Effects of recombinant human erythropoietin (rHuEPO) on tumor control in patients with cancer-induced anemia

Onkologie

Volumn 28, Issue 4, 2005, Pages 216-221

  Vaupel, Peter ^a   Dunst, Jürgen ^b   Engert, Andreas ^c   Fandrey, Joachim ^d   Feyer, Petra ^e   Freund, Mathias ^f   Jelkmann, Wolfgang ^g  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

^b MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY HOSPITAL ESSEN   (Germany)

^e Vivantes Klinikum   (Germany)

^f UNIVERSITY OF ROSTOCK   (Germany)

^g UNIVERSITY OF LÜBECK   (Germany)

Author keywords

Anemia; Erythropoietin; Hemoglobin concentration; Tumor oxygenation

Indexed keywords

CARBOPLATIN; ERYTHROPOIETIN RECEPTOR; HEMOGLOBIN; IFOSFAMIDE; IRON; RECOMBINANT ERYTHROPOIETIN; ANTINEOPLASTIC AGENT;

ANEMIA; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER INDUCED ANEMIA; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CORRELATION ANALYSIS; ERYTHROCYTE TRANSFUSION; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; HYPOXIA; NONHUMAN; OXYGENATION; PRACTICE GUIDELINE; QUALITY OF LIFE; REVIEW; SENSITIVITY ANALYSIS; UTERINE CERVIX CANCER; ARTICLE; BLOOD; CLINICAL PRACTICE; COMORBIDITY; HEALTH CARE COST; MORTALITY; NEOPLASM;

ANEMIA; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; COMORBIDITY; ERYTHROPOIETIN, RECOMBINANT; HEALTH CARE COSTS; HEMOGLOBINS; HUMANS; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES;

EID: 20844442466     PISSN: 0378584X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000084033     Document Type: Review

References (30)

1. Vaupel P, Thews O, Mayer A, Höckel S, Höckel M: Oxygenation status of gynecologic tumors: What is the optimal hemoglobin level? Strahlenther Onkol 2002;178:727-731.
2. Vaupel P, Kelleher DK, Höckel M: Oxygen status of malignant tumors: Pathogenesis of hypoxia and significance for tumor therapy. Semin Oncol 2001;28(Suppl 8):29-35.
3. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Tumor oxygenation in anemic rats: Effects of erythropoietin treatment versus red blood cell transfusion. Acta Oncol 1995;34:379-384.
4. Kelleher DK, Matthiensen U, Thews O, Vaupel P: Blood flow, oxygenation, and bioenergetic status of tumors after erythropoietin treatment in normal and anemic rats. Cancer Res 1996;56:4728-4734.
5. Becker A, Stadler P, Lavey RS, Hänsgen G, Kuhnt T, Lautenschläger C, Feldmann HJ, Molls M, Dunst J: Severe anemia is associated with poor tumor oxygenation in head and neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys 2000;46:459-466.
6. Münstedt K, Volzing M, von Georgi R: Hemoglobin levels during radiation therapy and their influence on local control and survival of patients with endometrial carcinoma. Oncol Rep 2004;11:711-717.
7. Altun M, Demiral AN, Meral R, Kaytan E, Cosar R, Disci R, Dizdar Y: Prognostic significance of hemoglobin concentration in nasopharyngeal carcinoma: Does treatment-induced anemia have negative effect? In Vivo 2003;17:483-487.
8. Ludwig H, Fritz E, Kotzmann H, Hocker P, Gisslinger H, Barnas U: Erythropoietin treatment of anemia associated with multiple myeloma. N Engl J Med 1990;322:1693-1699.
9. Abels RI: Recombinant human erythropoietin in the treatment of the anaemia of cancer. Acta Haematol 1992;87(Suppl 1):4-11.
10. Glaspy J, Bukowski R, Steinberg D, Taylor C, Tchekmedyian S, Vadhan-Raj S: Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218-1234.
11. Littlewood TJ, Bajetta E, Nortier JW, Vercammen E, Rapoport B: Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: Results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865-2874.
12. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA: Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer 2002;95:888-895.
13. Rizzo JD, Lichtin AE, Woolf SH, Seidenfeld J, Bennett CL, Cella D, Djulbegovic B, Goode MJ, Jakubowski AA, Lee SJ, Miller CB, Rarick MU, Regan DH, Browman GP, Gordon MS; American Society of Clinical Oncology. American Society of Hematology: Use of epoetin in patients with cancer: Evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology. J Clin Oncol 2002;20:4083-4107.
14. Thews O, Koenig R, Kelleher DK, Kutzner J, Vaupel P: Enhanced radiosensitivity in experimental tumours following erythropoietin treatment of chemotherapy-induced anaemia. Br J Cancer 1998;78:752-756.
15. Stüben G, Thews O, Pöttgen C, Knühmann K, Vaupel P, Stuschke M: Recombinant human erythropoietin increases the radiosensitivity of xenografted human tumours in anaemic nude mice. J Cancer Res Clin Oncol 2001;127:346-350.
16. Stüben G, Thews O, Pöttgen C, Knühmann K, Sack H, Stuschke M, Vaupel P: Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol 2003;179:620-625.
17. Stüben G, Pöttgen C, Knühmann K, Schmidt K, Stuschke M, Thews O, Vaupel P: Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys 2003;55:1358-1362.
18. Thews O, Kelleher DK, Vaupel P: Erythropoietin restores the anemia-induced reduction in cyclophosphamide cytotoxicity in rat tumors. Cancer Res 2001;61:1358-1361.
19. Blohmer JU, Urschnidt F, Petry U, Weise G, Sehouli J, Kimmig R, Kohls A, Lichtenegger W: 6th interim analysis of a prospective, randomized, open and controlled AGO- and NOGGO-intergroup study: Sequential adjuvant chemo-radiotherapy with vs. without epoetin alfa for patients with high-risk cervical cancer. Proc Am Soc Clin Oncol 2003;22: Abstract 1798.
20. Bohlius J, Langensiepen S, Schwarzer G, Seidenfeld J, Piper M, Bennet C, Engert A: Erythropoietin for patients with malignant disease. Cochrane Database Syst Rev 2004;3:CD003407. DOI:10.1002/14651858.CD003407.pub2.
21. Bohlius J, Langensiepen S, Schwarzer G, Engert A on behalf of the Cochrane Hematological Malignancies Group: Does erythropoietin improve overall survival of patients with malignancies? Final analysis of a comprehensive meta-analysis. Onkologie 2003;26(Suppl 5):25, V276.
22. Henke M, Laszig R, Rübe C, Schäfer U, Haase KD, Schilcher B, Mose S, Beer KT, Burger U, Dougherty C, Frommhold H: Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: Randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255-1260.
23. Joiner B, Hirst VK, McKeown SR, McAleer JJA, Hirst DG: The effect of recombinant human erythropoietin treatment on tumour radiosensitivtiy and cancer-associated anaemia in the mouse. Br J Cancer 1993;68:720-726.
24. Weiss G: Eisen, Infektion und Anämie - eine klassische Triade. Wien Klin Wochenschr 2002;114:357-367.
25. Leyland-Jones B, BEST Investigators and Study Group: Breast cancer trial with erythropoietin terminated unexpectedly. Lancet Oncol 2003;4:459-460.
26. Larsson A-M, Landberg G, Pahlman S, Albertsson M: Erythropoietin enhances response to treatment in patients with advanced breast cancer. Acta Oncol 2004;43:594-597.
27. Goodnough LT, Skikne B, Brugnara C: Erythropoietin, iron, and erythropoiesis. Blood 2000;96:823-833.
28. Jelkmann W, Wagner K: Beneficial and ominous aspects of the pleiotropic action of erythropoietin. Ann Hematol 2004;83:673-686.
29. Acs G, Zhang PJ, McGrath CM, Acs P, McBroom J, Mohyeldin A, Liu S, Lu H, Verma A: Hypoxia-inducible erythropoietin signaling in squamous dysplasia and squamous cell carcinoma of the uterine cervix and its potential role in cervical carcinogenesis and tumor progression. Am J Pathol 2003;162:1789-1806.
30. Batra S, Perelman N, Luck LR, Shimada H, Malik P: Pediatric tumor cells express erythropoietin and a functional erythropoietin receptor that promotes angiogenesis and tumor cell survival. Lab Invest 2003;83:1477-1478.